Kyprianou N (2000) Induction of apoptosis by alpha1-adrenoceptor antagonists in benign prostatic

hyperplasia and prostate cancer. Prostate Cancer Prostatic Dis 3:S24–S25. https://doi.org/10.

1038/sj.pcan.4500450

Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-

adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60:

4550–4555

Lin SC et al (2007) Prazosin displays anticancer activity against human prostate cancers: targeting

DNA and cell cycle. Neoplasia 9:830–839. https://doi.org/10.1593/neo.07475

Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K (2020) Drug

repositioning in cancer: the current situation in Japan. Cancer Sci. https://doi.org/10.1111/cas.

14318

Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH (2005) Brachytherapy-

related dysuria. BJU Int 95:597–602. https://doi.org/10.1111/j.1464-410X.2005.05346.x

Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A (2009) Prostate

cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer

Screening Trial. Br J Cancer 101:843–848. https://doi.org/10.1038/sj.bjc.6605188

Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T (2006) Comparison of two

alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of

lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.

BJU Int 97:747–751., discussion 751. https://doi.org/10.1111/j.1464-410X.2006.06030.x

Prinz

H

et

al

(2017)

N-Heterocyclic

(4-phenylpiperazin-1-yl)methanones

derived

from

phenoxazine and phenothiazine as highly potent inhibitors of tubulin polymerization. J Med

Chem 60:749–766. https://doi.org/10.1021/acs.jmedchem.6b01591

Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, D’Amico AV (1999)

Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a

pilot study. Int J Radiat Oncol Biol Phys 45:563–566. https://doi.org/10.1016/s0360-3016(99)

00246-1

Roehrborn CG, Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower

urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029–1035. https://doi.org/

10.1097/01.ju.0000097026.43866.cc

Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T (2006) Clinical

efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in

patients with benign prostatic hyperplasia. Int J Urol 13:15–20. https://doi.org/10.1111/j.

1442-2042.2006.01222.x

Tsuritani S, Nozaki T, Okumura A, Kimura H, Kazama T (2010) A prospective, randomized,

controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms

associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to

25 mg thrice daily. Urol Int 85:80–87. https://doi.org/10.1159/000315994

Urushiyama H et al (2019) Naftopidil reduced the proliferation of lung fibroblasts and bleomycin-

induced lung fibrosis in mice. J Cell Mol Med 23:3563–3571. https://doi.org/10.1111/jcmm.

14255

Walden PD, Gerardi C, Lepor H (1999) Localization and expression of the alpha1A-1, alpha1B and

alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 161:635–

640

8

Drug Repositioning of the Phenylpiperazine Derivative Naftopidil in. . .

119